Class information for:
Level 2: CLOPIDOGREL//PRASUGREL//TICAGRELOR

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
966 10690 35.0 75%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
8 4 CARDIAC & CARDIOVASCULAR SYSTEM//PERIPHERAL VASCULAR DISEASES//CARDIOL 1276458
131 3       HEMATOLOGY//HAEMOPHILIA//TRANSFUSION 66936
966 2             CLOPIDOGREL//PRASUGREL//TICAGRELOR 10690
310 1                   CLOPIDOGREL//PRASUGREL//TICAGRELOR 3676
4304 1                   TRANSIENT ISCHEMIC ATTACK//TIA//ABCD2 SCORE 1808
5185 1                   ASPIRIN RESISTANCE//ASPIRIN//PFA 100 1660
12453 1                   2ND MESSENGER PHARMACOLOGY//3 FMPPOB 3333//30 MG D 904
17435 1                   CILOSTAZOL//CLIN PHARMACOKINET PHARMACODYNAM METAB//TRIPLE ANTIPLATELET THERAPY 599
17743 1                   TICLOPIDINE//TICLOPIDINE HYDROCHLORIDE//E5510 585
19606 1                   SALICYLURIC ACID//SALICYLATE HYDROXYLASE//SALICYLATE DETERMINATION 497
23008 1                   PARTICLE COUNTING METHOD//WHOLE BLOOD PLATELET AGGREGATION//SPONTANEOUS PLATELET AGGREGATION 361
25152 1                   DIPYRIDAMOLE//VASODILATOR DRUG//MOPIDAMOL 289
31777 1                   INDOBUFEN//CAS 106498991//INDOBUFEN ENANTIOMERS 148
35730 1                   TRIFLUSAL//HTB//CAS 322 79 2 93
36936 1                   CASE MIX GROUP CLASSIFICATION//CHARISMA TRIAL//ECON WORKING GRP 70

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 CLOPIDOGREL authKW 2947235 15% 65% 1581
2 PRASUGREL authKW 1066791 4% 87% 431
3 TICAGRELOR authKW 899591 3% 85% 369
4 ASPIRIN RESISTANCE authKW 679200 2% 94% 253
5 ASPIRIN authKW 667167 11% 21% 1129
6 CILOSTAZOL authKW 644799 3% 65% 349
7 ANTIPLATELET THERAPY authKW 413994 3% 43% 341
8 PLATELET REACTIVITY authKW 361716 2% 69% 185
9 TRANSIENT ISCHEMIC ATTACK authKW 268231 3% 32% 296
10 TICLOPIDINE authKW 257493 2% 51% 178

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Peripheral Vascular Diseases 63011 23% 1% 2444
2 Cardiac & Cardiovascular System 33822 23% 1% 2439
3 Hematology 26684 16% 1% 1687
4 Pharmacology & Pharmacy 9264 19% 0% 2046
5 Clinical Neurology 5770 11% 0% 1226
6 Medicine, General & Internal 5278 12% 0% 1251
7 Medicine, Research & Experimental 398 4% 0% 375
8 Medical Laboratory Technology 314 1% 0% 124
9 Primary Health Care 251 1% 0% 62
10 Chemistry, Medicinal 119 2% 0% 193

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 SINAI THROMBOSIS 82932 0% 62% 47
2 HEARTDRUG S 67237 0% 65% 36
3 MED JACKSONVILLE 64933 1% 29% 78
4 TIMI STUDY GRP 55108 1% 20% 97
5 CARDIOL 51638 16% 1% 1712
6 STROKE PREVENT UNIT 31085 1% 20% 55
7 ST ANTONIUS PLATELET FUNCT 30146 0% 81% 13
8 HOP UNIV NORD 24666 0% 79% 11
9 CLIN PHARMACOKINET PHARMACODYNAM METAB 21016 0% 82% 9
10 UPPSALA CLIN 20399 1% 11% 64

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 PLATELETS 82465 2% 13% 222
2 THROMBOSIS RESEARCH 52282 4% 4% 435
3 THROMBOSIS AND HAEMOSTASIS 34038 3% 4% 347
4 STROKE 30360 4% 3% 393
5 CEREBROVASCULAR DISEASES 19065 1% 5% 142
6 JOURNAL OF THROMBOSIS AND THROMBOLYSIS 17474 1% 6% 107
7 INTERNATIONAL JOURNAL OF STROKE 11453 1% 6% 65
8 JOURNAL OF STROKE & CEREBROVASCULAR DISEASES 10655 1% 4% 94
9 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 9796 1% 3% 117
10 JACC-CARDIOVASCULAR INTERVENTIONS 6991 1% 5% 55

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class		 LCSH search Wikipedia search
1 CLOPIDOGREL 2947235 15% 65% 1581 Search CLOPIDOGREL Search CLOPIDOGREL
2 PRASUGREL 1066791 4% 87% 431 Search PRASUGREL Search PRASUGREL
3 TICAGRELOR 899591 3% 85% 369 Search TICAGRELOR Search TICAGRELOR
4 ASPIRIN RESISTANCE 679200 2% 94% 253 Search ASPIRIN+RESISTANCE Search ASPIRIN+RESISTANCE
5 ASPIRIN 667167 11% 21% 1129 Search ASPIRIN Search ASPIRIN
6 CILOSTAZOL 644799 3% 65% 349 Search CILOSTAZOL Search CILOSTAZOL
7 ANTIPLATELET THERAPY 413994 3% 43% 341 Search ANTIPLATELET+THERAPY Search ANTIPLATELET+THERAPY
8 PLATELET REACTIVITY 361716 2% 69% 185 Search PLATELET+REACTIVITY Search PLATELET+REACTIVITY
9 TRANSIENT ISCHEMIC ATTACK 268231 3% 32% 296 Search TRANSIENT+ISCHEMIC+ATTACK Search TRANSIENT+ISCHEMIC+ATTACK
10 TICLOPIDINE 257493 2% 51% 178 Search TICLOPIDINE Search TICLOPIDINE

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 WINTER, MP , KOZINSKI, M , KUBICA, J , ARADI, D , SILLER-MATULA, JM , (2015) PERSONALIZED ANTIPLATELET THERAPY WITH P2Y12 RECEPTOR INHIBITORS: BENEFITS AND PITFALLS.POSTEPY W KARDIOLOGII INTERWENCYJNEJ. VOL. 11. ISSUE 4. P. 259 -280 171 89% 8
2 SILLER-MATULA, JM , TRENK, D , SCHROR, K , GAWAZ, M , KRISTENSEN, SD , STOREY, RF , HUBER, K , (2013) RESPONSE VARIABILITY TO P2Y(12) RECEPTOR INHIBITORS EXPECTATIONS AND REALITY.JACC-CARDIOVASCULAR INTERVENTIONS. VOL. 6. ISSUE 11. P. 1111-1128 149 95% 34
3 MALLOUK, N , LABRUYERE, C , RENY, JL , CHAPELLE, C , PIOT, M , FONTANA, P , GRIS, JC , DELAVENNE, X , MISMETTI, P , LAPORTE, S , (2012) PREVALENCE OF POOR BIOLOGICAL RESPONSE TO CLOPIDOGREL A SYSTEMATIC REVIEW.THROMBOSIS AND HAEMOSTASIS. VOL. 107. ISSUE 3. P. 494 -506 158 95% 20
4 WURTZ, M , GROVE, EL , (2012) INTERINDIVIDUAL VARIABILITY IN THE EFFICACY OF ORAL ANTIPLATELET DRUGS: DEFINITIONS, MECHANISMS AND CLINICAL IMPORTANCE.CURRENT PHARMACEUTICAL DESIGN. VOL. 18. ISSUE 33. P. 5344-5361 200 75% 17
5 SILLER-MATULA, JM , TRENK, D , SCHROR, K , GAWAZ, M , KRISTENSEN, SD , STOREY, RF , HUBER, K , (2015) HOW TO IMPROVE THE CONCEPT OF INDIVIDUALISED ANTIPLATELET THERAPY WITH P2Y(12) RECEPTOR INHIBITORS - IS AN ALGORITHM THE ANSWER?.THROMBOSIS AND HAEMOSTASIS. VOL. 113. ISSUE 1. P. 37 -52 137 94% 9
6 BONELLO, L , TANTRY, US , MARCUCCI, R , BLINDT, R , ANGIOLILLO, DJ , BECKER, R , BHATT, DL , CATTANEO, M , COLLET, JP , CUISSET, T , ET AL (2010) CONSENSUS AND FUTURE DIRECTIONS ON THE DEFINITION OF HIGH ON-TREATMENT PLATELET REACTIVITY TO ADENOSINE DIPHOSPHATE.JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. VOL. 56. ISSUE 12. P. 919 -933 86 95% 438
7 HALL, R , MAZER, CD , (2011) ANTIPLATELET DRUGS: A REVIEW OF THEIR PHARMACOLOGY AND MANAGEMENT IN THE PERIOPERATIVE PERIOD.ANESTHESIA AND ANALGESIA. VOL. 112. ISSUE 2. P. 292-318 187 66% 56
8 ROLLINI, F , FRANCHI, F , ANGIOLILLO, DJ , (2016) SWITCHING P2Y(12)-RECEPTOR INHIBITORS IN PATIENTS WITH CORONARY ARTERY DISEASE.NATURE REVIEWS CARDIOLOGY. VOL. 13. ISSUE 1. P. 11 -27 72 95% 15
9 TANTRY, US , GURBEL, PA , (2013) ANTIPLATELET DRUG RESISTANCE AND VARIABILITY IN RESPONSE: THE ROLE OF ANTIPLATELET THERAPY MONITORING.CURRENT PHARMACEUTICAL DESIGN. VOL. 19. ISSUE 21. P. 3795-3815 132 95% 6
10 FRANCHI, F , ANGIOLILLO, DJ , (2015) NOVEL ANTIPLATELET AGENTS IN ACUTE CORONARY SYNDROME.NATURE REVIEWS CARDIOLOGY. VOL. 12. ISSUE 1. P. 30 -47 108 71% 37

Classes with closest relation at Level 2


Rank Class id link
1 437 ACUTE CORONARY SYNDROME//CARDIAC & CARDIOVASCULAR SYSTEM//MYOCARDIAL INFARCTION
2 697 MEAN PLATELET VOLUME//PLATELETS//HEMATOLOGY
3 188 STROKE//INTRACEREBRAL HEMORRHAGE//THROMBOLYSIS
4 1157 FIBRINOLYSIS//PLASMINOGEN ACTIVATOR INHIBITOR 1//PAI 1
5 767 WARFARIN//CYP2C9//VKORC1
6 1311 PROSTAGLANDIN D 2//CRTH2//MOL BEHAV BIOL
7 2062 VON WILLEBRAND DISEASE//VON WILLEBRAND FACTOR//ENDOCAN
8 466 NSAIDS//NON STEROIDAL ANTI INFLAMMATORY DRUGS//COX 2 INHIBITORS
9 129 DRUG ELUTING STENT//CARDIAC & CARDIOVASCULAR SYSTEM//PERCUTANEOUS CORONARY INTERVENTION
10 3716 CARBOXYLESTERASE//DRUG METAB BIOPHARMACEUT//CES2

Go to start page